Further, our observation that the sensitivity to DTX in chemoresistant PCa cells was significantly augmented when EXI and RELA were used in combination with LEDGF/p75 silencing suggests that combining LEDGF/p75 inhibitors with these SMGRs could be an effective therapeutic strategy to increase prostate tumor response to taxanes. The gene discussed is RELA; the disease is prostate neoplasm.